Quality Management Systems (QMS) are defined by the MDR as formalised systems that document processes, responsibilities, and procedures to ensure and continually improve the standard of company activities. To obtain CE marking and market devices in European Union, an effective Quality Management System that complies with EU MDR 2017/745 is must.
Article 10 of EU MDR 2017/745 explains the general obligation of manufacturers to place their products in the EU market. Article 10 of the EU MDR 2017/745 also comprises the requirements for implementing and maintaining a Quality Management System capable of addressing particular issues to ensure device quality and safety. Manufacturers of devices are expected to establish, document, implement, maintain, and keep up to date all the device documents to continually aid the improvement of the quality management system.
Quality Management System (QMS) must address at least the following:
A strategy for regulatory compliance, which includes conformity assessment procedures and procedures for change management and control for the device
The system must consist of general safety and performance requirements and methods to address the same
The system must define the management’s responsibility
The system must include resource management methodologies which should contain information on the selection and control of suppliers and sub-contractors
The system must include risk management methodologies as per Section 3 of Annex I
The system must include clinical evaluation data along with post-market clinical follow-up (PMCF) as per Article 61 and Annex XIV
The system must include data on product realization, which should involve information such as planning, design, development, production, and service provision
The system must ensure the verification of the UDI assignments as per Article 27(3) for all relevant devices and should also ensure consistency and validity of the information provided as per Article 29
The system must contain data on the setup, implementation, and maintenance of a post-market surveillance system as per Article 83
The system must include communication protocols with competent authorities, notified bodies, other economic operators, customers and/or other stakeholders
The system must include methodologies for reporting serious events and field safety corrective actions in the context of vigilance
The system must also include methodologies of management of corrective actions and verification of their effectiveness
The system must include data on processes for monitoring and measurement of output data, data analysis and product improvement
Mapping of ISO 13485:2016 clauses to the MDR QMS requirements
How will a QMS be assessed under the EU MDR?
The quality management system of a manufacturer will be evaluated as part of the EU MDR Annex IX to XI- conformity assessment procedures. A Notified Body will do conformity evaluation for all devices except Class I.
Can ISO 13485:2016 QMS certificate holders bypass or claim EU MDR compliant QMS by themselves?
No, to be compliant with EU MDR the manufacturer is required to obtain a QMS assessment w.r.t Article 10(9) by a notified body in case of Class II & III. For a class I, the manufacturer must establish a corresponding QMS and include the same declaration in the self-declared DoC
Is 13485:2016 mandatory for MDR in addition to Article 10(9)?
No, the ISO 13485:2016 is not mandatory. However, the Quality Management System ISO 13485:2016 ensures entry to various global markets.
Disclaimer: Regulations/legislations are subjected to changes from time to time and the author claims no responsibility for the accuracy of information.
The French Poly Implant Prostheses (PIP) breast implant controversy prompted medical rules to be revised and formed new Medical Devices and In-Vitro Devices Regulations to safeguard public health. As per the European Medicines Agency (EMA) definition, a medicinal device is a substance or combination of substances intended to treat, prevent or diagnose a disease, or restore, correct or modify physiological functions by exerting a pharmacological immunological or metabolic action.
Medical devices, or device parts, are increasingly being produced for use with medicinal items, which might range from a basic prefilled syringe to more complex autoinjectors to medical devices incorporated as sensors in tablets. Regulatory bodies have created specialised capabilities and requirements over the last decade due to the increased integration of medicines and devices seen in the latest generation of combination products. To achieve fast and proper market access for new combination products, manufacturers must adequately understand the unique requirements in each country, and the development of combination products entails a specific pattern of engagement between manufacturers and regulatory bodies. Based on their primary mode of action, products that combine a medicinal product (or substance) and a medical device are governed by Regulation (EU) 2017/745 or Directive 2001/83/EC.
How is a product categorised as a medicinal product or a medical device based on its mode of action?
As per the EU MDR 2017/745, the product is controlled as a:
medical device when the action of the medicinal substance is auxiliary to the action of the medical device,
medicinal product when the action of the medicinal substance is prominent and not supplementary to the action of the medical device.
For example, an insulin injector pen’s principal action is insulin administration. As a result, the injector pen will be classified as a medicinal product.
The necessity of a declaration of conformity and an EU certificate issued by a notified authority for the evaluation of compliance of the device part and the Drug-Device Combination marketing authorisation dossier is the most significant change brought about by Article 117 of EU MDR. Suppose these conformity assessment documents are excluded from the dossier. In that case, the applicant will be asked to give an opinion from a notified body on the device part’s compliance with the relevant requirements of EU MDR Annex I. A notified body is a conformity assessment service provider appointed by the National Competent Authority to assess the conformity of medical devices before being placed on the Union market.
When the device is integrated with a medicinal substance where the action of that substance is principal, or when the medical device administers a medicinal product forming a single integral product, such devices are considered an integral product (combination of medical device and medicinal product). They shall be governed by Directive 2001/83/EC or Regulation (EC) No 726/2004 and the relevant general safety and performance requirements set out in Annex I of Regulation (EU) 2017/745. The devices must meet the following criteria before they may be placed on the market:
The device and the medicinal product should be combined into a single integral product
The single integral product should not be reused
The single integrated product is only meant to be used in combination
Marketing Authorisation Applications (MAA)
An application by the Marketing Authorisation Holder (MAH)/applicant to a European regulatory body seeking authorisation to commercialise a pharmaceutical inside the European Union is known as a Marketing Authorisation Application (MAA). Once obtained, the centralised marketing authorisation is valid in all EU Member States and EEA-EFTA countries (Iceland, Norway, and Liechtenstein). According to Annex I of Regulation (EU) 2017/745, the MAA shall provide the following for a combination device starting on 26 May 2021:
Declaration of Conformity, and the CE certificate issued by a notified body for the device part having a CE mark
An opinion from a notified body on the conformity of the device part, if it does not hold a CE mark, Declaration of Conformity, and the CE certificate irrespective of the class of the device
Additional information of the benefit/risk assessment of the medicinal product when requested
Where a CE mark has not been issued to the device component on its own, the manufacturer must reach out to a NB and obtain their opinion on the device conformity and provide the NBO report in the MAA
In case the documents mentioned above are issued following the Medical Device Directives 93/42/EEC or 90/385/EEC, then they are still valid and can be used to support the requirements throughout the transition period, which lasts until 26 May 2024.
According to the European Medicines Agency (EMA) or the National Competent Authority (NCA), these documents must be provided in the initial MAA for the medicinal product, and if not, they must be produced before an opinion on the medicinal product application may be granted. Failure to submit the appropriate documentation may cause the evaluation period to be delayed.
If any changes to the design, intended purpose of the device part, or a new version are launched after the Marketing Authorization has been granted to the manufacturer, the necessary declaration of conformity, CE certificate, and notified body opinion should be submitted to the EMA/NCA. If the revisions influence the device’s quality, safety, or efficacy, the applicant/Marketing Authorisation Holders (MAH) must file a variation application, consulting the Medicines Competent Authority that gave the marketing authorisation (if the change is unclear). As part of regulatory compliance, the relevant member states require the Mutual Recognition Procedure (MRP)/Repeat Use Procedure (RUP) application after submitting the variation application. The dossiers for this application include the General Safety and Performance Requirements (GSPR) of the MDR and Annex I of Directive 2001/83/EC, Section 3.2’s point 12 of Directive 2001/83/EC as amended by Article 117 of the MDR, and supporting documents like the declaration of conformity, certificate of conformity or notified body opinion.
The European Public Assessment Report (EPAR) contains information on the submission and evaluation of materials, procedures, findings, and conclusions of the marketing authorisation application (MAA) to the EMA/NCA.
Co-Packaged Medical Devices
If a medical device is provided as part of the secondary packaging of a marketed medicinal product (co-packaged) and does not form an integral part of the medicinal product, the Marketing Authorisation Holder/applicant must ensure that their co-packaged medical device is CE marked, meets the MDR’s general safety and performance requirements, and is entirely compliant with the MDR before it can be placed on the market. Spoons, measuring cups, inhalers, and spacers are co-packaged medical devices. MDR 2017/745 must be followed by self-CE marked Class I devices.
Article 117 of the Regulation requires Notified Body involvement for European market authorisation of a medicinal product that incorporates an integral medical device or drug-device combination product. The EMA has released an FAQ to help the combination products’ manufacturers understand Article 117 requirements better. Manufacturers must keep in mind that the summary report of NBO will be issued by the notified body only after they verify if all the GSPR requirements are met adequately. Based on their opinion report, the medicines agency decides on the products’ MAA.
Is the NBO report mandatory to be submitted to the MAA?
There are 2 ways to do this: 1. If the device is CE marked already, the manufacturer must submit a DoC and a copy of the CE certificate for the device. 2. If the device is not CE marked, obtain the NBO report (assessment of GSPR) and submit it to the authority along with your MAA application
What is a Single Integrated Drug-Device product?
If a medical device used to administer a medicinal product is placed on the market in such a way that the device and medicinal product form a single integral product which is intended exclusively for use in the given combination and which is not reusable, that single integral product shall be governed by Directive 2001/83/EC or Regulation (EC) No 726/2004, as applicable.
What are a few examples of Drug-Device Combination products?
Pre-filled syringes, inhalers, pre-filled pens, an antibody combined with a therapeutic drug, transdermal patches, and insulin pump. Co-packaging examples are a Drug or vaccine vial packed with a syringe and a dose-dispenser medication.
Disclaimer: Regulations/legislations are subjected to changes from time to time and the author claims no responsibility for the accuracy of information.
Medical devices are those products used to prevent, diagnose, treat, and monitor the many diseases known to humankind. Medical devices and medicines play an equally important role in treating human beings. To learn more about medical devices, read our article on the definition of a medical device. This article discusses the nomenclature of medical devices and examples of these.
What is the nomenclature of medical devices?
To simply put it, the nomenclature is the naming of a medical device. Although medical devices are classified into different risk classes, they should be named so that it is universally identified. Standardised nomenclature facilitates this easy identification.
A nomenclature is needed to simplify trade and tracking among the different regulatory authorities, Ministries of Health, and other organisations that regulate medical devices.
A standardised nomenclature aids in the following aspects:
Grouping and classification of medical devices.
Registration under different regulatory bodies or Ministries of Health
Streamlined procurement and distribution
Grouping of medical devices in various electronic health records and medical device databases
Vigilance reporting, field safety and post-market surveillance
The different device nomenclatures available are as follows:
GMDN or Global Medical Device Nomenclature.
EMDN or European Medical Device Nomenclature
UMDNS or Universal Medical Device Nomenclature System
Other nationally developed nomenclature systems
Global Medical Device Nomenclature (GMDN)
About 10% of countries use Global Medical Device Nomenclature worldwide. It is a system of internationally accepted descriptors used to identify medical devices. The GMDN Agency manages GMDN codes, a non-profit organisation.
GMDN is a 5-digit code containing the following information:
GMDN Term Name: Anaesthesia ventilator
GMDN Code: 34851
GMDN Definition: A mains electricity (AC-powered) stand-alone, automatic cycling device used to assist and control alveolar ventilation during general anaesthesia and is compatible with inhaled anaesthetic agents. It has fewer functions and is less complex to operate than an intensive care ventilator but adequately meets the patient’s ventilation needs for oxygen (O2) and carbon dioxide (CO2) exchange to maintain normal blood gas concentrations. The device provides a mechanical means to deliver the breathing gas to the patient in a controlled pattern. It is equipped with alarms to warn of changes in respiration or the onset of unsafe operating conditions.
GMDN was introduced for a variety of regulatory purposes. GMDN is based on the ISO 15225: Medical device nomenclature data structure’. Read more about the frequently asked questions about GMDN here.
European Medical Device Nomenclature (EMDN)
European Medical Device Nomenclature or EMDN is introduced due to Article 26 of EU Regulation 2017/745 of Medical devices and Article 23 of EU Regulation 2017/746 of in-vitro diagnostic medical devices. Like GMDN, it plays a considerable role in device nomenclature and serves various regulatory purposes. One of the primary uses is while registering a medical device in EUDAMEDwhere it is closely linked to UDI-DI.
Structure of EMDN
The European Medical Device Nomenclature is characterised by its alphanumeric structure and is established in a seven-level hierarchical tree where it clusters medical devices into three primary levels:
Categories: the first hierarchical level – alphanumeric.
Groups: the second hierarchical level – 2 numbers indicating group.
Types: the third hierarchical level – a series of numbers 1,2,3,4 and 5.
EMDN was adopted from the Classificazione Nazionale Dispositivi medici (CND) classification. The EMDN can be accessed at the EMDN list. European Medical Device Nomenclature categorises into three primary levels, categories, groups, and types. A category comprises several groups composed of various kinds of medical devices.
Universal Medical Device Nomenclature System (UMDNS)
Universal Medical Device Nomenclature System or UMDNS was developed by the Emergency Care Research Institute (ECRI). Many nations have adopted this standard around the world. UMDNS is used in inventory control, work order control, and regulatory systems applications. It is a 5-digit code unique code and a term for different types of medical devices. One can find the UMDNS code list here. UMDNS is updated monthly.
CND nomenclature or ‘Classificazione Nazionale Dispositivi medici’ was developed by Italian Ministry of Health. In addition to Italy, it is also used in Portugal and Greece. The guidance document on CND nomenclature explains the basic principles and structure of CND, which also applies to EMDN as EMDN was adopted from CND nomenclature. Following this, medical devices are clustered into three levels:
Is UDI the same as GMDN?
Both Unique Device Identification System (UDI) and GMDN are used in device identification. However, the two have some fundamental differences. UDI is inferior because of its lack of unity. It does not have a structure; therefore, device identification becomes more difficult with UDIs. Nonetheless, it is an effective tool for the traceability of medical devices. FDA utilises UDIs for medical device identification. The user guide to GUDID explains how the UDIs are managed in US FDA’s database, GUDID.
Can EMDN be accessed free of charge?
The EMDN is accessible to all stakeholders- free of charge. Hence, it can be utilised by a non-exhaustive list of stakeholders such as manufacturers, patients, research organisations, practitioners, hospitals, etc. The EMDN can also be downloaded from here.
Is there a guidance document that helps economic operators to map the EMDN information into the forthcoming EUDAMED database?
Good manufacturing practices are the procedures that must be followed in order to comply with the guidelines set forth by regulatory agencies that oversee the authorization and licencing of the manufacture and sale of medical devices.
The GMP document released on 30th March 2022 for Medical and IVD products replaced the GMP document released by ANVISA in 2013. In this article, we will discuss the Significant changes that were made in the latest 2022 Regulations, which supersedes the 2013 version.
In Art 35 2022 GMP Document, under the document review and archive section, it is explicitly mentioned that – “All digitally stored documents and records shall be backed up.”
In Art 71 2022 GMP Document, under the Personal health and hygiene section, it is now clearly explained that – “Any individual who, upon medical examination or observation by supervisors, appears to be in a health condition which could affect the product shall be removed from operations until the health condition is deemed adequate.”
In Art 87 2022 GMP Document underlabels and instructions for use, there is an additional point which states – “In the case of importers, the approval documentation referred to in “Labels and instructions for use” article may be recorded in a specific document in lieu of the history record of the product.”
In Art 112 2022 GMP Document under Distribution Records section, it is now mentioned as:
Each manufacturer shall maintain distribution records which include or reference:
I – the name and address of the consignee.
II – risk: combination of probability of occurrence and severity of damage.
III – any number control used for traceability.
Previously in the 2013 GMP document, it was mentioned as:
Each manufacturer shall maintain distribution records, including or making reference to: (i)Names and addresses of the consignee; (ii) Identification and amount of products shipped, with shipment date; (iii) Any numerical control used for traceability.
In Art 114 2022 GMP Document under Identification and traceability of batch production units’ section, there is an additional point added which states- “Each manufacturer shall establish and maintain a program for maintenance, adjustment and, where necessary, cleaning of equipment to ensure that all manufacturing specifications are met.” This is in addition to the identification of the units that are manufactured with every product history record.
In Art 118 2022 GMP Document, under the Non-conforming components and products section, there is an additional point added which states – “The disposal of the products referred to as “non-conforming” shall be documented, and a record of the justification and manual or electronic signature of the person-in-charge for the disposal of such non-conforming products or components shall be kept.”
In Art 120-VIII 2022 GMP Document, under the Corrective and preventive actions section, there is additional information added which states – Each manufacturer shall establish and maintain procedures to determine the collection of products and other field actions for those products that are already distributed. The quality process to determine the corrective actions in regard to the identified potential causes shall be based on a valid statistical technique for detecting recurring quality problems, where applicable.”
In Art 123 2022 GMP Document under the Quality Audit section, there is an additional point added which states – “Those in charge of conducting the quality audit cannot be directly responsible for the matters under audit.”
CHAPTER 10 in 2022 GMP Document (Final Provisions) is additionally introduced – The chapter includes rules such as:
“The documentation evidencing compliance with the requirements set out in this Resolution shall be made available whenever requested by the health regulatory agencies.”
“Failure to comply with the provisions contained in this Resolution constitutes a health violation, under the terms of Law No. 6.437, of August 20, 1977, without prejudice to applicable civil, administrative and criminal liabilities”
“The following are hereby revoked: I – the Resolution of the Collegiate Board of Directors – RDC No. 16, of March 28, 2013, published in the Federal Official Journal No. 61, of April 1, 2013, Section 1, p. 75;
II – Normative Instruction – IN No. 8, of December 26, 2013, published in the Federal Official Journal No. 252, of December 30, 2013, Section 1, p. 758.”
The EU MDR 2017/745 imposes more stringent requirements for Class I devices. Under the new regulations, Manufacturers must righty classify a medical device and provide technical documentation following the device class. The risk class under MDD could change under MDR. In some cases, medical devices could be up classified from Class I to Class II a/b or Class III. Please read our article on the classification of medical devices to understand how to classify your current device per MDR.
Step 1: Integrate MDR into the existing Quality Management System.
This allows the correct documentation to be created following the risk classification of the device.
Step 2: Confirm whether the product is a medical device under the scope of MDR.
Confirm that the product meets the definition of a medical device as stated in Article 2 of EU MDR based on its intended use and primary mode of action. In some cases, the product may be out of the scope of MDR and may be termed as a medical device ‘accessory ’. EU MDR also states how accessories for a medical device is also to be classified on its own apart from the main medical device.
Step 3: Confirm whether the medical device is a Class I medical device.
It must be noted that several MDD Class I devices will be reclassified under the MDR as per the new classification criteria in Annex VIII, such as most software (rule11) and devices made up of chemicals or combinations of substances (rule 21).
Step 4: Pre-market procedures.
Verify that the device meets the General Safety and Performance Requirements (GSPR).
A proper and well-established risk management system should be implemented. Manufacturers must ensure that the associated risks are identified, analysed and appropriate corrective actions are taken. This must be guaranteed throughout the product’s lifecycle and documented. When standard specifications are available, Manufacturers must adhere to them unless they can demonstrate that they have adopted a solution that is at least as safe and effective.
The Manufacturer should periodically update the clinical evaluation report, risk management and post-market reports.
Conduct Clinical evaluations
All devices require clinical evaluation, Class I devices are not exempted from this requirement. A clinical evaluation report must contain essential information such as device descriptions, literature reports and post-market surveillance reports to name a few. MDR also emphasises the need to consider available alternatives and the acceptability of the benefit-risk ratio.
Prepare an up-to-date technical file.
The Manufacturer will draw up the technical documentation that demonstrates the conformity of their devices with the specific requirements of the MDR. Technical documentation is mentioned in Annex II and III of EU MDR.
The Manufacturer is obligated to keep the file updated and make them available to competent authorities, notified bodies and the authorised representative.
The technical file must contain the following elements. The detailed information can be found in Annex II of EU MDR.
Device description and specification, variants, and accessories
Information to be supplied by the Manufacturer
Information on Design and manufacturing
General Safety and Performance Requirements
Verification and validation of product
Demonstration of Conformity
The documents in the technical file should be made available in the language accepted in the Member State in which the device is sold. Please read our article on EU Requirements for translations to understand this requirement specified in EU MDR.
Involvement of Notified Bodies
Most Class I devices do not require the involvement of a Notified Body. However, device Classes ‘Ir’, ‘Is’ and ‘Im’ have this requirement. ‘Ir’ devices are those which are reusable instruments. ‘Is’ are devices to be used in a sterile condition. ‘Im’ are those devices with a measuring function. For these devices, the involvement of Notified Bodies is limited to audit and the NB assesses those specific controls. For example, an “Is” device assessment of NB would involve auditing the Sterilisation process and controls.
Prepare Instructions for Use and Labelling
Medical device manufacturers must ensure that the instructions for use and labels are available in languages accepted within the Member State they decide to market in. The instruction for use must indicate the safety and performance information so that its users are aware of its intended use. The instructions for use (IFUs) should have drawings and internationally accepted symbols. Read our article on Information to be supplied by manufacturers to understand more about this topic.
The Declaration of conformity (DoC) is a document signed by the Manufacturer that states the device fulfils the requirements set forth by MDR. For more information, read our article on Declaration of conformity.
Step 6: Affix CE mark.
CE mark should be placed on the medical device to show compliance. If it cannot be placed on the product itself, it must be placed on the packaging.
Before placing in the EU market, all devices must be registered on EUDAMED. EUDAMED is a secure, web-based European Databank on Medical Devices. Although Class I devices are not much of a threat to human life, they must be made available on EUDAMED. It ensures that the device information is accessible to the public.
Transitional provisions are in place to help manufacturers transition to MDR from the directives. Article 120 of EU MDR gives an idea of the exemptions from MDR and greatly helps manufacturers by providing more time to meet the requirements.
The following conditions must be met to be able to market a device according to Directive 93/42/EEC until 26 May 2024:
The device complies with Directive 93/42/EEC.
The device has not undergone significant changes in device design or intended purpose.
The device has a valid Declaration of Conformity (DoC)
The post-market surveillance, Market Surveillance, Vigilance and Registration of economic operators and devices requirements are met.
Does a Class I Device manufacturer require an ISO certificate for the Quality Management System?
Not necessarily. The Class I manufacturer must have an established QMS, and obtaining a certification is not mandated. Although globally, there is a significant benefit for the Manufacturer to hold an ISO QMS certification. Major markets worldwide accept ISO 13485 certificate as one of the key entry factors into their geography. A few key markets, such as Canada, Japan, Australia, Singapore, and Malaysia, require ISO Certification. The ISO 13485 certificate is recognised worldwide as a significant standard for a quality management system for medical device manufacturers.
Should Class I Device DoC contain the reference to MDR Annex (s)?
Yes, but this has been considered of less importance while drafting the DoC. Declaration of Conformity (DoC) must mention the respective Annex(s) in the MDR that it has complied with for any device class. This is one of the required information to be entered while performing product registrations in many countries.
What is the conformity procedure for Class I devices?
The conformity procedure for all Class I devices is mentioned in the flow chart.
Annex XVI products are those for which a manufacturer claims only an aesthetic or another non-medical purpose but are like medical devices in terms of functioning and risk profile. These categories of products were added in the new Regulation to establish production and surveillance standards for these previously unregulated products to protect users’ health and safety.
LIST OF GROUPS OF PRODUCTS WITHOUT AN INTENDED MEDICAL PURPOSE REFERRED TO IN ARTICLE 1(2)
Contact lenses or other items intended to be introduced into or onto the eye.
Products intended to be totally or partially introduced into the human body through surgically invasive means for the purpose of modifying the anatomy or fixation of body parts except for tattooing products and piercings.
Substances, combinations of substances, or items intended to be used for facial or other dermal or mucous membrane filling by subcutaneous, submucous or intradermal injection or other introduction, excluding those for tattooing.
Equipment intended to be used to reduce, remove, or destroy adipose tissue, such as equipment for liposuction, lipolysis or lipoplasty.
High-intensity electromagnetic radiation (e.g., infra-red, visible light and ultra-violet) emitting equipment intended for use on the human body, including coherent and non-coherent sources, monochromatic and broad-spectrum, such as lasers and intense pulsed light equipment, for skin resurfacing, tattoo or hair removal or other skin treatment.
Equipment intended for brain stimulation that apply electrical currents or magnetic or electromagnetic fields that penetrate the cranium to modify neuronal activity in the brain.
When is this coming into force?
Manufacturers of Annex XVI products have six months from the official release of the standard specifications, which is scheduled in Spring 2022, to comply with the regulation. As a result, manufacturers must examine how this may affect their product(s) right now and what further testing and proof will be required to demonstrate compliance with common specifications.
Technical and clinical requirements (other than standards) that give a way of complying with the legal duties applicable to a device are referred to as “common specifications.” Existing harmonised standards for similar medical equipment will be considered.
Annex XVI products do not have to comply with the MDR until the Commission adopts and publishes the CS for the individual product categories, which is expected to be no later than May 26, 2020, or when CS is adopted, whichever is the latest. Individual Member States’ national classification of Annex XVI products as medical devices will continue to apply until then, and compliance with applicable national medical device legislation will be required.
How will this impact manufacturers of these products?
Manufacturers of Annex XVI products sold in Europe (including the UK) will have to be compliant with the requirements laid out in the MDR for general medical devices to ensure they are safe for use.
In addition to complying with the relevant standard specifications, manufacturers of Annex XVI products will need to meet several other obligations such as GSPR, equivalence approach, clinical data, and post-market surveillance. These include, but are not limited to, ensuring that:
Correct classification of the device based on the risk impact (as per Annex VIII)
Comply to the Common Specifications listed for those products
Require demonstrating clinical benefit in accordance with Annex XIV & annex XV
There is a person in charge of regulatory compliance
Distributors and importers in the supply chain are compliant
Sufficient financial coverage is in place in respect of a manufacturer’s potential liability
The new vigilance reporting deadlines have been met, and an annual safety update report has been issued.
Manufacturers must undergo a conformity assessment, which will be conducted by a notified authority, as part of the regulatory requirements. The device must then be marked with a CE mark and a declaration of conformity. Furthermore, a basic unique device identification (UDI) must be assigned and provided to the UDI database, critical information about themselves, and the authorised representative and importer if they are based outside of the EU, needs to be submitted to Eudamed.
The manufacturer must also comply with post-market surveillance and vigilance requirements, including reporting remarkable events to the appropriate authorities, such as the MHRA in the UK.
Manufacturers of Annex XVI products will have additional requirements, such as verifying that the device has been accurately classified against the revised risk classification criteria in Annex VIII of the MDR and complying with the necessary standard specifications. They will also need to ensure they have a person in charge of regulatory compliance, have enough insurance to cover potential manufacturer liability, meet the new vigilance reporting deadlines, and generate an annual periodic safety update report.
The manufacturer is also responsible for ensuring that the product’s distributors and importers have performed their duties under Articles 13 and 14 of the regulation.
Please read Article 10 of the MDR for further detail on manufacturer obligations.
How to comply with the legal requirements?
Determine which risk category your device belongs to.
Ensure your device conforms with the MDR and the standard specifications for these groups of products.
Pass a compliance assessment conducted by a notified body if required.
Draw a declaration of conformity and affix a CE mark to the device.
Provide the UDI database with a basic unique device identification (UDI) assigned to the device.
If the manufacturer is outside the EU, submit essential information about the manufacturer, authorised representative, and importer to the electronic system (Eudamed).
Place your CE marked device on the market or put it into service anywhere in Europe.
Meet the standards for post-market surveillance and vigilance, such as implementing field safety remedial actions and reporting major events to the appropriate authority.
Examples of Annex XVI products
Non-prescription coloured contact lenses
Solid contour body implants
Liposuction body sculpting equipment
Equipements for hair removal (using infra-red, ultraviolet, visible light)
FAQs (Frequently Asked Questions)
Devices with non-medical purposes are classified under which rule?
Apply Annex VIII classification rules in the EU MDR.
Do I need an Authorised Representative for marketing devices without intended medical purpose?
Yes, as per Regulation an AR must be appointed to sell these devices in the Union market.
Have the Common Specifications been released?
No, as of the date Apr 2022 the CS are under the draft stage. Follow our website updates to know more about this or subscribe to our newsletter to get the updates.